ST. PAUL, Minn.--(BUSINESS WIRE)--CoreBiome, a genomics platform company that is transforming microbiome innovation with proprietary laboratory methods and big-data analytics, today announced the appointment of Dr. Daniel Pomp, Ph.D., a world leader in agricultural and biomedical genomics, to its Board of Directors.
Daniel Pomp has over 30 years of experience in the biomedical genomics and agricultural biotechnology spaces. Dr. Pomp previously co-founded GeneSeek, a global biotechnology company providing high-quality DNA testing services to agribusiness and veterinary medicine that was acquired by Neogen in 2010. He is an active angel investor, serves as a member of the Advisory Board for AgriCapital, a boutique investment bank in NYC, and sits on the Scientific Advisory Board for Locus Biosciences and the Board of Directors for the Center for Entrepreneurial Development. He is currently a Professor in the Departments of Genetics (School of Medicine) and Nutrition (School of Public Health) at the University of North Carolina – Chapel Hill.
Dr. Pomp said, "The CoreBiome platforms represent a dramatic increase in the amount of information researchers can get out of a microbiome study. This is already changing the way microbiome screening is performed in a wide range of applications. I am looking forward to working with the team in leveraging these powerful technologies.”
The CoreBiome Board is chaired by Dr. Pamela York, an advisor and university life science startup expert, currently General Partner of Capita3. “We are delighted to have Daniel join the Board,” said Dr. York. “His successes in the genomics and agriculture industries, along with his history of building and investing in early stage companies, will be instrumental in positioning CoreBiome for growth and strategic opportunities.”
CoreBiome co-founder and CEO Dan Knights stated, “This is an important step toward being the globally trusted partner in microbiome research and development. With the addition of Dr. Pomp to the Board of Directors, CoreBiome continues to build out the roster of trusted advisors to achieve its mission of enabling faster and smarter discovery of microbiome therapeutics and diagnostics.”
CoreBiome is a genomics platform company focused on accelerating discovery for customers in the pharmaceutical, agriculture, and research communities, to unleash the translational potential of the microbiome. The Company’s proprietary BenchMarkTM, BoosterShotTM, BoostArrayTM, and Core AnalysisTM platforms provide fast and information-rich characterizations of microbial diversity and function, paired with machine learning and expert analytics. For more information about CoreBiome, visit http://www.corebiome.com/.